サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726168

糖尿病前症の市場規模、シェア、動向分析レポート：薬剤クラス別、年齢層別、地域別、セグメント別予測、2025年～2030年

Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), By Age Group (Children, Adult, Elderly), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 134 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
糖尿病前症の市場規模、シェア、動向分析レポート：薬剤クラス別、年齢層別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年04月07日
発行: Grand View Research
ページ情報: 英文 134 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

糖尿病前症市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の糖尿病前症市場規模は2030年までに5億8,570万米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 10.9％で成長すると予測されています。市場成長の要因はいくつかあります。主要促進要因の1つは、糖尿病前症の有病率の上昇と肥満率の増加です。肥満は糖尿病の開発と相関関係があります。例えば、2023年6月にセントルイスのワシントン大学が発表したところによると、米国では3,700万人以上が糖尿病に罹患しており、そのうち40％以上が肥満を経験しており、この状態は糖尿病患者の最大半数に関連しています。成人の約3分の1を占める約9,600万人のアメリカ人が糖尿病予備軍であると推定されています。肥満は、座りがちなライフスタイルや食生活の乱れと関連することが多く、糖尿病前症発症の重大な危険因子です。糖尿病前症患者の増加は、世界の肥満の流行と一致しており、これら2つの健康問題の関連性を示しています。

さらに、遺伝的素因や家族歴も大きく寄与しています。生活習慣が大きな役割を果たす一方で、遺伝的要因が個人の糖尿病予備軍に対する感受性に影響することもあり、特定の集団が糖尿病予備軍になりやすくなっています。

糖尿病前症市場レポートハイライト

  • 薬剤クラス別では、ジグアナイド系が2024年に78.8%の最大売上シェアで市場を牽引。メトホルミンはジグアナイド薬クラスの薬剤であり、糖尿病治療の第一選択薬です。メトホルミンは、糖尿病前症の治療と進行抑制のために最も一般的に配合される適応外薬剤です。
  • 年齢層別では、成人セグメントが2024年に最大の売上シェアで市場をリードしました。成人の座りがちで病気を引き起こすライフスタイルの増加が、この年齢層セグメントの主要成長要因です。糖尿病前症の有病率の増加と認知度の向上が、このセグメントの成長を牽引しています。
  • 北米は、先進的医療インフラ、高い認知度、臨床検査のための高い研究活動により、2024年の売上高シェア41.3％で市場を独占しました。この地域は先進的で強力な研究インフラを提供しています。地域に根ざしたプログラムや支援グループは、糖尿病予備軍に健康的な食事や定期的な身体活動といったサステイナブルライフスタイルの変化を促します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 糖尿病前症市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 糖尿病前症市場：薬剤クラスビジネス分析

  • 薬剤クラス市場シェア、2024年と2030年
  • 薬剤クラスセグメントダッシュボード
  • 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
  • ジグアニド
  • チアゾリジンジオン
  • グルカゴン様ペプチド-1作動薬（GLP-1）
  • SGLT2阻害剤
  • DPP-4阻害剤
  • その他

第5章 糖尿病前症市場：年齢層別ビジネス分析

  • 年齢層市場シェア、2024年と2030年
  • 年齢層セグメントダッシュボード
  • 市場規模と予測と動向分析（年齢層別、2018～2030年）
  • 幼児（12～18歳）
  • 成人（18～49歳）
  • 高齢者（50歳以上）

第6章 糖尿病前症市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Novo Nordisk A/S
    • ValbIoTis
    • RESVERLOGIX
    • Caelus Health
    • Scimar
    • Boston Pharmaceuticals
    • APHAIA PHARMA AG
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Prediabetes Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 Global Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 6 North America Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 8 North America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 9 U.S. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 U.S. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 11 Canada Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Canada Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 13 Mexico Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 14 Mexico Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 15 Europe Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Europe Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 18 U.K. Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 19 U.K. Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 20 Germany Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Germany Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 22 France Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 France Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 24 Italy Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 25 Italy Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 26 Spain Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Spain Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 28 Denmark Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 29 Denmark Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 30 Norway Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Norway Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 32 Sweden Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Sweden Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 37 Japan Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Japan Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 39 China Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 40 China Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 41 India Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 India Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 43 South Korea Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 44 South Korea Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 45 Australia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Australia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 47 Thailand Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Thailand Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 49 Latin America Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Latin America Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 52 Brazil Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Brazil Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 54 Argentina Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Argentina Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Prediabetes Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 59 South Africa Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 South Africa Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 63 UAE Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 64 UAE Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Prediabetes Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Prediabetes Market, by Age Group, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prediabetes Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Drug Class and Age Group Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 Prediabetes Market Dynamics
  • Fig. 12 Prediabetes Market: Porter's Five Forces Analysis
  • Fig. 13 Prediabetes Market: PESTLE Analysis
  • Fig. 14 Prediabetes Market: Drug Class Segment Dashboard
  • Fig. 15 Prediabetes Market: Drug Class Market Share Analysis, 2024 & 2030
  • Fig. 16 Diguanide Market, 2018 - 2030 (USD Million)
  • Fig. 17 Thiazolidinediones Market, 2018 - 2030 (USD Million)
  • Fig. 18 Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
  • Fig. 19 SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • Fig. 20 DPP-4 Inhibitors Market, 2018 - 2030 (USD Million)
  • Fig. 21 Others Market, 2018 - 2030 (USD Million)
  • Fig. 22 Prediabetes Market: Age Group Segment Dashboard
  • Fig. 23 Prediabetes Market: Age Group Market Share Analysis, 2024 & 2030
  • Fig. 24 Children (12-18 years) Market, 2018 - 2030 (USD Million)
  • Fig. 25 Adults (18-49) Market, 2018 - 2030 (USD Million)
  • Fig. 26 Elderly (50+) Market, 2018 - 2030 (USD Million)
  • Fig. 27 Prediabetes Market Revenue, By Region
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Country Dynamics
  • Fig. 32 U.S. Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada Country Dynamics
  • Fig. 34 Canada Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Country Dynamics
  • Fig. 36 Mexico Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 38 UK Country Dynamics
  • Fig. 39 UK Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Country Dynamics
  • Fig. 41 Germany Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 42 France Country Dynamics
  • Fig. 43 France Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Country Dynamics
  • Fig. 45 Italy Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain Country Dynamics
  • Fig. 47 Spain Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark Country Dynamics
  • Fig. 49 Denmark Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway Country Dynamics
  • Fig. 51 Norway Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Country Dynamics
  • Fig. 53 Sweden Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Country Dynamics
  • Fig. 56 Japan Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 57 China Country Dynamics
  • Fig. 58 China Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 59 India Country Dynamics
  • Fig. 60 India Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea Country Dynamics
  • Fig. 62 South Korea Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia Country Dynamics
  • Fig. 64 Australia Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand Country Dynamics
  • Fig. 66 Thailand Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil Country Dynamics
  • Fig. 69 Brazil Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina Country Dynamics
  • Fig. 71 Argentina Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East & Africa Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa Country Dynamics
  • Fig. 74 South Africa Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia Country Dynamics
  • Fig. 76 Saudi Arabia Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE Country Dynamics
  • Fig. 78 UAE Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait Key Country Dynamics
  • Fig. 80 Kuwait Prediabetes Market, 2018 - 2030 (USD Million)
  • Fig. 81 Company Categorization
  • Fig. 82 Company Market Position Analysis
  • Fig. 83 Strategic Framework
目次
Product Code: GVR-4-68040-221-4

Prediabetes Market Growth & Trends:

The global prediabetes market size is anticipated to reach USD 585.7 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.9% from 2025 to 2030. Several factors drive the market growth. One of the main factors driving is the rising prevalence of prediabetes and increasing obesity rates. Obesity correlates with the development of diabetes. For instance, according to Washington University in St. Louis in June 2023, over 37 million individuals in the U.S. are affected by diabetes, with over 40% of them experiencing obesity, a condition associated with up to half of all diabetes cases. It is estimated that approximately 96 million Americans, constituting roughly one-third of adults, are living with prediabetes. Obesity, often linked with sedentary lifestyles and poor diet, is a significant risk factor for developing prediabetes. The rise in prediabetes cases has coincided with the global obesity epidemic, demonstrating the connection between these two health problems.

Moreover, genetic predisposition and family history also contribute significantly. While lifestyle factors play a predominant role, genetic factors can influence an individual's susceptibility to developing prediabetes, making specific populations more prone to the condition.

Prediabetes Market Report Highlights:

  • Based on the drug class, the diguanide segment led the market with the largest revenue share of 78.8% in 2024. Metformin, a drug under the diguanide class is the first choice of drug for the treatment of prediabetes. It is the most commonly prescribed off-label drug for the treatment and slowing down the progression of prediabetes.
  • Based on the age group, the adult segment led the market with the largest revenue share in 2024. The increasing sedentary and disease-causing lifestyle among adults is the primary growth factor for this age group segment. The increasing prevalence of prediabetes along with increased awareness are driving the growth of this segment.
  • North America dominated the market with the revenue share of 41.3% in 2024, owing to the advanced healthcare infrastructure, high awareness, and high research activities for clinical trials. The region offers an advanced and strong research infrastructure. Community-based programs and support groups empower individuals with prediabetes to make sustainable lifestyle changes, such as healthy eating and regular physical activity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Age Group
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Prediabetes Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Prediabetes Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Diguanide
    • 4.4.1. Diguanide Market, 2018 - 2030 (USD Million)
  • 4.5. Thiazolidinediones
    • 4.5.1. Thiazolidinediones Market, 2018 - 2030 (USD Million)
  • 4.6. Glucagon-like peptide-1 agonists (GLP-1)
    • 4.6.1. Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
  • 4.7. SGLT2 inhibitors
    • 4.7.1. SGLT2 inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. DPP-4 inhibitors
    • 4.8.1. DPP-4 inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prediabetes Market: Age Group Business Analysis

  • 5.1. Age Group Market Share, 2024 & 2030
  • 5.2. Age Group Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Age Group, 2018 to 2030 (USD Million)
  • 5.4. Children (12-18 years)
    • 5.4.1. Children (12-18 years) Market, 2018 - 2030 (USD Million)
  • 5.5. Adults (18-49)
    • 5.5.1. Adults (18-49) Market, 2018 - 2030 (USD Million)
  • 5.6. Elderly (50+)
    • 5.6.1. Elderly (50+) Market, 2018 - 2030 (USD Million)

Chapter 6. Prediabetes Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamic
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamic
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamic
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamic
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamic
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamic
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamic
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamic
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamic
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamic
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamic
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamic
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamic
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamic
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamic
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamic
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamic
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamic
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamic
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamic
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamic
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamic
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamic
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Novo Nordisk A/S
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Valbiotis
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. RESVERLOGIX
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Caelus Health
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Scimar
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Boston Pharmaceuticals
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. APHAIA PHARMA AG
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AstraZeneca
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Bristol-Myers Squibb Company
      • 7.5.9.1. Participant's overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Pfizer Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives